| CAS NO: | 79660-72-3 |
| 包装 | 价格(元) |
| 500mg | 电议 |
| 1 g | 电议 |
| 5 g | 电议 |
| 10 g | 电议 |
| Cas No. | 79660-72-3 |
| 别名 | 氟罗沙星; RO 23-6240; AM-833 |
| 化学名 | 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid |
| Canonical SMILES | CN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)CCF)F |
| 分子式 | C17H18F3N3O3 |
| 分子量 | 369.34 |
| 溶解度 | DMF: 0.1 mg/ml,DMSO: 15 mg/ml,PBS (pH 7.2): 10 mg/ml |
| 储存条件 | 4°C, protect from light |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Fleroxacin (RO 23-6240) is a broad-spectrum antimicrobial fluoroquinolone. Fleroxacin (Ro 23-6240) is a new trifluorinated quinolone exhibiting high activity against a broad spectrum of gram-negative and gram-positive bacteria. Fleroxacin is characterized pharmacokinetically by a long elimination half-life (9 to 10 h) and high concentrations in plasma (e.g., maximum concentration of 2.3 micrograms/ml after an oral dose of 200 mg)[1]. Fleroxacin (Ro 23-6240) is effective against Haemophilus ducreyi in vitro. Fleroxacin (Ro 23-6240), 200 or 400 mg as a single oral dose, is efficacious therapy for microbiologically proven chancroid in patients who do not have concurrent HIV-1 infection. Among HIV-1-infected men, a single dose of 200 or 400 mg of fleroxacin is inadequate therapy for chancroid[2][3]. References: |
m.cnreagent.com